Department of Pathobiology, Ontario
Veterinary College, University of Guelph, Guelph, Ontario N1G 2W1,
Canada,1 and Veterinary Diagnostic
Laboratory, College of Veterinary Medicine, Iowa State University,
Ames, Iowa 500112
Received 21 December 2000/Returned for modification 16 February
2001/Accepted 13 March 2001
Five domains of antigenic importance were previously mapped on the
nucleocapsid protein (N) of the porcine reproductive and respiratory
syndrome virus (PRRSV), and a domain comprised of the 11 C-terminal-most amino acids (residues 112 to 123) was shown to be
essential for binding of N-specific conformation-dependent monoclonal
antibodies (MAbs). In the present study, the importance of individual
residues within this C-terminal domain for antigenicity was
investigated using eight different mutant constructs of N expressed in
HeLa cells. Single amino acid substitutions were introduced into the
C-terminal domain of the N protein, and the significance of individual
amino acids for MAb reactivity was determined by immunoprecipitation.
None of the MAbs tested recognized the mutant with a leucine-to-proline
substitution at residue 114 (L114P), while V112P, R113P, R113D, I115P,
and R116P reduced MAb binding significantly. Conversely, substitution
of amino acids at positions 118 (T118S) and 121 (P121A) had little
effect on MAb binding. Secondary-structure predictions indicate that
amino acids 111 to 117 form a beta-strand. In view of the fact that replacement of beta-strand-forming amino acids with proline elicited the greatest effect on MAb binding, it appears that secondary structure
in the C terminus of the N protein is an important determinant of
conformational epitope formation. While the crystal structure of the
PRRSV N protein remains to be determined, results from these studies
broaden our understanding of the secondary structures that make up the
PRRSV N protein and shed some light on how they may relate to function.
 |
INTRODUCTION |
Since its emergence in the late
1980s, the porcine reproductive and respiratory syndrome virus (PRRSV)
has spread widely throughout pig-producing countries, imposing a
considerable economic burden on the swine industry worldwide
(1). Clinical signs associated with the syndrome vary
greatly. In general, symptoms are more apparent in young pigs and are
often associated with respiratory illness leading to secondary
infections, while sows suffer primarily from reproductive problems
(22).
PRRSV is a small, enveloped RNA virus belonging to the family
Arteriviridae in the order Nidovirales
(3). The PRRSV genome is a nonsegmented, plus-strand RNA
molecule that is capped and polyadenylated (23). The
full-length genomic sequence for both the North American (2, 18,
27) and the European (15) genotypes of PRRSV has
been determined. The nonstructural proteins responsible for genome
replication are encoded in two large open reading frames (ORFs 1a and
1b) that comprise the 5'-terminal two-thirds of the genome. The
structural proteins are translated from a 3'-coterminal nested set of
subgenomic mRNAs that are synthesized via a discontinuous mechanism of
transcription (25). ORFs 2a, 2b (24), 3, and
4 (encoding GP2a, GP2b, GP3, and GP4) are thought to encode minor
envelope proteins, ORFs 5 (encoding GP5) and 6 (encoding M) encode
major envelope proteins, and ORF 7 encodes the nucleocapsid protein (N)
(5).
The N protein is a highly abundant protein that experiences relatively
little amino acid variability (11, 13). The early immunological response generated in PRRSV-infected pigs is directed mainly to the N protein, and this response, which can be detected as
early as 1 week postinfection (12), declines at a much
lower rate than that directed to the major structural proteins M and GP5 (30). Since the majority of antibodies produced during
PRRSV infection in pigs are specific for the N protein, for which major antigenic determinants are highly conserved, the N protein has been
targeted as a suitable candidate for the detection of virus-specific antibodies and diagnosis of the disease. Indeed, recombinant N protein
expressed either in insect cells (9, 16) or in
Escherichia coli (8) has been used as an
antigen in the development of indirect and competitive enzyme-linked
immunosorbent assays, respectively, for detection of serum antibodies
against PRRSV. These methods are relatively inexpensive, sensitive, and
easy to perform and therefore represent a feasible economic alternative
to the present methods that rely upon whole-virus antigen
(14). Therefore, knowledge of the antigenic makeup of the
PRRSV N protein would be beneficial in the development of more
effective detection methods.
In a previous study, a series of nine N protein deletion mutants
expressed in HeLa cells and a collection of N-specific monoclonal antibodies (MAbs) were used to identify antigenically important domains
on the PRRSV N protein (26). Of the five domains
identified, the C-terminal-most domain appeared to be critical for
correct folding of the N protein, as the mutant construct with a
deletion of 11 amino acids from its C terminus (designated C-11) was
unrecognizable by any of the conformation-dependent MAbs examined. In
light of the fact that the majority of N-specific MAbs produced in mice and in pigs are conformational (7, 10, 19), we wanted to investigate the structural nature of the C-terminal domain of the N
protein in greater detail by introducing specific mutations to assess
the role of individual C-terminal amino acids in MAb binding.
 |
MATERIALS AND METHODS |
Cells, viruses, and antibodies.
HeLa cells were maintained
at 37°C and 5% CO2 in Dulbecco's modified Eagle's
medium supplemented with 10% heat-inactivated fetal bovine serum (FBS)
(CanSera, Rexdale, Ontario, Canada). MARC-145 cells were maintained in
Dulbecco's modified Eagle's medium supplemented with 4%
heat-inactivated FBS. To prepare the recombinant vaccinia virus vTF7-3,
HeLa cells were infected at a multiplicity of infection (MOI) of 1 PFU/cell. At approximately 36 h postinfection, concomitant with
the appearance of severe cytopathic effects, cells were scraped into
the media and subjected to two cycles of freeze-thawing to release
virus particles. Cellular debris was removed by centrifugation at
1,500 × g for 10 min, and the clarified supernatant
was used as crude virus stock. To prepare the PRRSV isolate PA8
(27), MARC-145 cells were infected with an MOI of 5 PFU/cell. At 2 days postinfection, cells and supernatant were collected
and centrifuged for 10 min at 1,500 × g. The clarified
supernatant was used as crude virus stock. E. coli strains
XL1-Blue (Stratagene, La Jolla, Calif.) and DH5
were used as hosts
for generating N gene mutations after PCR mutagenesis and for
general-purpose cloning, respectively.
Generation of mouse ascites for the PRRSV-specific MAbs utilized in
this study is described elsewhere (19, 20, 28, 29). Ascites fluid for MAbs 2D6, 1D2, 2G7, and 7C10 was kindly provided by
D. Deregt at the Animal Disease Research Institute, Lethbridge, Alberta, Canada.
Construction of N gene mutants.
cDNA cloning of the N gene
from PRRSV isolate PA8 to produce pGEM3zf-ORF7 was described previously
(26). The N gene excised with BamHI from
pGEM3zf-ORF7 was subcloned into the BamHI site of pCITE-2c
(Novagen, Madison, Wis.) downstream of the T7 promoter producing
pCITE-ORF7. This construct was used as the parental plasmid for the
generation of N gene mutants by oligonucleotide-directed PCR
mutagenesis according to the QuickChange site-directed mutagenesis protocol (Stratagene). The desired amino acid replacements were incorporated into PCR-amplified fragments using the primer pairs listed in Table 1. PCR amplifications
were carried out using 15 ng of pCITE-ORF7 plasmid DNA; 300 ng of
forward and reverse primer; 1 mM concentrations each of dCTP, dGTP,
dATP, and dTTP; 1× PCR buffer [10 mM KCl, 10 mM
(NH4)2SO4, 20 mM Tris-HCl (pH 8.8),
2 mM MgSO4, 0.1% Triton X-100]; and 2.5 U of
Pfu DNA polymerase (Stratagene). The samples were subjected
to 12 cycles of amplification under the following conditions:
denaturation at 94°C for 30 s, primer annealing at 55°C for 1 min, and primer extension at 68°C for 8 min. Upon incorporation of
the oligonucleotide primers, a mutated plasmid containing staggered
nicks was generated. Following PCR cycling, the products were digested
with DpnI to remove the methylated and hemimethylated
parental plasmid DNA template. E. coli XL1-Blue cells were
transformed by heat shock with 1 µl of the PCR-DpnI digest
mixture containing the mutated plasmids. XL1-Blue competent cells were
used because of their ability to repair nicks in the mutated plasmid in
vivo. Random colonies were selected and plasmid DNA was prepared using
a QIAprep spin miniprep kit (Qiagen, Santa Clarita, Calif.). The
presence of desired mutations was verified by nucleotide sequencing in
both directions. Plasmid DNA for transfection experiments was prepared
using a plasmid midi kit (Qiagen) according to the manufacturer's
recommended procedures.
Protein expression and radiolabeling.
HeLa cells grown to
90% confluence in 100-mm-diameter dishes were infected at an MOI of 5 PFU/cell with vaccinia virus vTF7-3 and allowed to adsorb for 1 h
at 37°C with occasional rocking. Five milliliters of fresh medium
containing 10% FBS was added, and incubation continued for an
additional 1 h at 37°C. Transfection solution consisting of 8 µg of plasmid DNA, 30 µl of LipofectACE (Gibco BRL, Burlington,
Ontario, Canada), and 800 µl of OPTI-MEM (Gibco BRL) was incubated at
room temperature for 30 min prior to overlay on cells. At 2 h
postinfection, medium was removed and the transfection solution,
diluted with 6.5 ml of OPTI-MEM, was added to the cells. The
transfection solution was removed at 10 h postinfection, and cells were
labeled for 16 h with 50 µCi of Easy Tag EXPRESS protein
labeling mix ([35S]methionine and
[35S]cysteine; specific activity, 407 MBq/ml; New England
Nuclear, Boston, Mass.)/ml in methionine-free Eagle's minimal
essential medium (Sigma, Oakville, Ontario, Canada) supplemented with
2% FBS. The cells were harvested, washed twice with cold
phosphate-buffered saline, and resuspended in 600 µl of lysis buffer
(0.1% Triton X-100, 0.5% NP-40, 10 mM Tris-HCl [pH 7.4]) per dish.
After incubation for 10 min on ice, cell lysates were centrifuged at
14,000 rpm for 30 min in a microcentrifuge. The supernatant containing
the cytoplasmic fraction was collected for immunoprecipitation experiments.
Immunoprecipitation and SDS-polyacrylamide gel electrophoresis
analysis.
Thirty-microliter aliquots of labeled cell lysates
(equivalent to approximately 105 cells) were adjusted with
radioimmunoprecipitation assay (RIPA) buffer (1% Triton X-100, 1%
sodium deoxycholate, 150 mM NaCl, 50 mM Tris-HCl [pH 7.4], 10 mM
EDTA, 0.1% sodium dodecyl sulfate [SDS]) to a final volume of 100 µl and incubated for 2 h at room temperature with 1 µl of MAb
ascites fluid. The immune complexes were adsorbed to 10 mg of protein A
Sepharose CL-4B beads (Amersham Pharmacia Biotech, Baie d'Urfe,
Quebec, Canada) for 16 h at 4°C in 800 µl of RIPA buffer
containing a final concentration of 0.3% SDS. The precipitates,
collected by microcentrifugation in an Eppendorf 5415C microcentrifuge
at 6,000 rpm for 2 min, were washed twice with RIPA buffer and once
with wash buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl). Pellets were
resuspended in 20 µl of SDS sample buffer (10 mM Tris-HCl [pH 6.8],
25% glycerol, 10% SDS, 10%
-mercaptoethanol, 0.12% [wt/vol]
bromophenol blue) and heated for 5 min at 95°C. After
microcentrifugation in an Eppendorf 5415C microcentrifuge at 10,000 rpm
for 5 min, the supernatant was analyzed by SDS polyacrylamide gel
electrophoresis on 12% polyacrylamide gels. The gels were dried and
exposed to X-ray film at
70°C.
 |
RESULTS |
Construction and expression of mutant proteins.
Secondary-structure predictions indicate that amino acids 111 to 117 of
the N protein form a strong beta-strand, while the extreme C-terminal
amino acids form a coil structure (6). To examine the
contribution of the beta-strand to MAb binding, single amino acid
substitutions were introduced to replace individual residues in the
C-terminal domain of the PRRSV N protein. Valine at position 112 and
isoleucine at position 115, both of which are strong beta-strand
formers, were replaced with proline, a strong beta-strand breaker, to
construct mutants V112P and I115P, respectively. Arginine at position
113 was replaced with aspartic acid (R113D), effectively reversing the
charge and permitting the role of charge in MAb binding to be analyzed.
Arginine at position 113, leucine at position 114, and arginine at
position 116 were each replaced with proline in order to examine their effects on beta-strand structure and ultimately their involvement in
MAb binding (R113P, L114P and R116P, respectively). Two additional amino acids downstream of the putative beta-strand were mutated to
generate T118S and P121A. Threonine at position 118 was replaced with
serine (T118S) to assess the effect of a relatively conservative change
in this region, while proline at position 121 was replaced with alanine
(P121A) to examine the significance of chain flexibility. N-gene
mutants were generated by oligonucleotide-directed PCR mutagenesis
using the primer pairs listed in Table 1 to alter amino acid codons. A
total of eight mutants were constructed (Fig. 1), and the mutant proteins were
expressed in HeLa cells using the T7-based vaccinia virus expression
system.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 1.
(A) Illustration of five antigenically important domains
localized on the PRRSV N protein. Boxes flanked by numbers indicate
amino acid positions of the antigenic domains identified in the
previous study (26). Domains: I, amino acids 30 to 52; II,
37 to 52; III, 52 to 69; IV, 69 to 112; V, 112 to 123. (B) Illustration
of amino acid substitutions made in the C terminus of the PRRSV N
protein. Substitutions are indicated at their respective positions
below the wild-type (WT) sequence. Dots represent identical amino
acids, and numbers indicate amino acid positions. The desired amino
acid replacements were introduced into PCR-amplified fragments using
the primer pairs listed in Table 1.
|
|
The specificity of MAbs was initially confirmed using the authentic
viral N protein as well as the recombinant N protein expressed in HeLa
cells, and the confirmed N-specific MAbs were subsequently tested for
their C terminus dependency using the C-11 deletion construct (Table
2). A total of 10 MAbs (ISU15B, ISU15C,
ISU15E, ISU15Fd, ISU15Fd-11, ISU15Fd-32, K9-3, K9-5, K9-9, and 2D6)
were identified as C terminus dependent, and thus a total of 19 MAbs were used for this study, including the 9 MAbs previously characterized (SDOW17, VO17, EP147, SR30, MR40, JP25, 1D2, 2G7, and 7C10)
(26).
Immunoreactivitiy of the beta-strand mutants with C-terminus
dependent MAbs.
The immunoreactivities of individual MAbs with the
beta-strand mutant proteins were determined by immunoprecipitation to
assess the interaction of antibody with antigen expressed in its
natural environment under the normal physiological conditions of the
eukaryotic cell. Expression of the mutant proteins was first confirmed
by immunoprecipitation with the C-terminus independent MAb ISU15A (Table 2). MAb ISU15A detected all eight mutant proteins with equal
affinity, indicating that the mutants were efficiently expressed in
this system and that the levels of protein expression were comparable
(Fig. 2A). Experiments were repeated a
minimum of two times to validate the results. Antibody binding was
scored as follows: an interaction was considered positive if the N
protein was detectable after 48 h of exposure, weakly positive if
the N protein was detectable after 1 week of exposure, and negative if
the N protein was undetectable even after 1 week of exposure. Thirteen
different binding patterns were discerned from these immunoprecipitation studies. MAb ISU15B displayed a unique reactivity profile with the mutant proteins since replacement of arginine at
position 113 with proline (R113P) abolished MAb binding (Fig. 2B, lane
5) while reversal of the amino acid charge from positive to negative by
replacing arginine with aspartic acid (R113D) had no effect (Fig. 2B,
lane 6). In almost every other case, with the exception of a very weak
signal for MAbs SDOW17 and K9-9 (Fig. 2I, lane 6), replacement of
arginine at position 113 with proline or aspartic acid affected MAb
binding in a similar manner. MAbs ISU15C (Fig. 2C, lane 11), EP147,
7C10, and 1D2 (Fig. 2M, lane 11) were the only MAbs that did not detect
the P121A mutant. MAbs ISU15E, K9-5, and MR40 (Fig. 2D) appear to be
particularly sensitive to mutations in the putative beta-strand domain,
as only the T118S and P121A mutants were detected. MAb K9-3 was unusual
in that it was the only MAb unable to detect the T118S mutant (Fig. 2E, lane 10). ISU15Fd-11 was the only MAb capable of detecting the I115P
mutant with high affinity (Fig. 2F, lane 8); however, a weak signal was
seen for MAbs ISU15Fd-32, SDOW17, and K9-9 (Fig. 2G and I, lanes 8).
Finally, VO17 (Fig. 2K, lane 4), 2D6, and 2G7 (Fig. 2N, lane 4) were
the only MAbs able to detect the V112P mutant. Occasionally, point
mutations reduced, but did not completely abolish, MAb binding, and
these were scored as weakly positive (Fig. 2G, lanes 8 through 10;
2H, lanes 9 and 10; 2I, lanes 6, 8, 9, and 10; 2J, lane 10, and 2N,
lane 11). However, in a few cases, particularly with ISU15Fd-11,
ISU15Fd, SDOW17, and SR30, point mutations actually enhanced binding
affinity (Fig. 2F, H, I, and J, respectively, lanes 11). In the case of
enhanced binding, the P121A mutant appeared to be favored. Since the
MAbs displayed variable affinity for the PA8 N protein, scores were
determined relative to the individual MAb's affinity for the wild-type
N protein. The immunoreactivity scores are summarized in Table 2. Interestingly, none of the MAbs tested were able to recognize the L114P
mutant and very few detected the neighboring mutants I115P and R116P.
Conversely, mutation of T118S and P121A had very little negative effect
on MAb binding. Sixty-eight percent (13 out of 19) of the MAbs tested
displayed a unique reactivity profile with the mutants, suggesting that
while all of the MAbs examined were C terminus dependent, they differ
with respect to their epitope specificities.

View larger version (45K):
[in this window]
[in a new window]
|
FIG. 2.
Immunoprecipitation of N protein point mutants. (A)
ISU15A; (B) ISU15B; (C) ISU15C; (D) ISU15E (representative of MAbs K9-5
and MR40); (E) K9-3; (F) ISU15Fd-11; (G) ISU15Fd-32; (H) ISU15Fd; (I)
SDOW17 (representative of K9-9); (J) SR30; (K) VO17; (L) JP25; (M)
EP147 (representative of 1D2 and 7C10); (N) 2D6 (representative of
2G7), [I( )T( )], uninfected and untransfected; [I(+)T( )],
vTF7-3 infected and untransfected; [I(+)T(+)], vTF7-3 infected and
pCITE-2c transfected.
|
|
 |
DISCUSSION |
The present study was conducted in order to characterize
the involvement of the 11 C-terminal-most amino acids in
conformation-dependent MAb binding and, in doing so, contribute to our
understanding of the antigenic structure of the PRRSV N protein. The
importance of the C terminus was highlighted in a previous study, where
deletion of as little as 11 amino acids from the C terminus of the
PRRSV N protein (North American isolate PA8) abolished binding of
conformation-dependent MAbs (26). The C terminus has also
been recognized as being an important determinant of discontinuous
epitope formation in the N protein of the European lineage of PRRSV. In
this case, deletion of either 23 or 31 amino acids from the C terminus
of N proteins derived from European PRRSV isolates destroyed binding of
conformation-dependent MAbs (17, 21). These findings
support the notion that the C terminus of the N protein is critical for the generation of discontinuous epitopes. Moreover,
C-terminus-dependent epitopes appear to be significant in vivo, as
conformation-dependent MAbs were the only MAbs able to
efficiently compete with PRRSV-positive porcine sera in a
competitive enzyme-linked immunosorbent assay (21).
Therefore, C-terminus-dependent epitopes may be among the most dominant
of the PRRSV N protein, at least in the natural host.
A structural role for the C terminus was alluded to in a recent report
aimed at identifying antigenic determinants on the Lelystad virus (LV)
N protein. In this case, to circumvent the structural changes
associated with deleting C-terminal amino acids, a chimera between the
N protein of LV and lactate dehydrogenase elevating virus (LDV),
another member of the family Arteriviridae, was constructed
(17). In the chimeric protein, C-terminal amino acids 111 to 128 of the LV N protein (the European N protein is 128 amino acids
long, whereas the North American N protein is 123 amino acids) were
replaced by the corresponding amino acids of the LDV N protein. Of
those substituted amino acids, only residues which make up the putative
beta-strand domain are identical to the LV N protein sequence (Fig.
3). Interestingly, amino acids 110 to 118 (North American numbering scheme) comprise one of the four invariable
regions common to the N protein of both North American and European
genotypes of PRRSV (11). Replacement with LDV C-terminal
amino acids was able to restore conformation-dependent MAb binding.
Given that only those C-terminal amino acids that make up the putative
beta-strand are identical between the LV and LDV N proteins, this
result suggests that this region of the C terminus plays an important
role in determining N protein conformation. These observations
correlate well with our results in which the most dramatic effect on
C-terminus dependent MAb binding was observed when amino acids
comprising the beta-strand were mutated. Therefore, it is likely that
these extreme C-terminal amino acids have been conserved due to their
requirement for nucleocapsid function and/or structure, thus
substantiating the importance of this region of the N protein.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 3.
Illustration of the sequence conservation in the C
terminus of N proteins from PA8 virus, LV, and LDV. Vertical lines
designate amino acids common to all three viruses. The box defines the
stretch of absolutely conserved amino acids, while the shaded area
inside highlights amino acids comprising the predicted beta-strand.
Amino acid position numbers in descriptions above and below the diagram
apply to the PA8 sequence only. GenBank accession numbers: PA8,
AF066068; LV, U03040; LDV, AF092283.
|
|
We found that C-terminal amino acids comprising the beta-strand exert
the greatest influence on N protein structure, as determined by binding
of C-terminus-dependent MAbs to mutant proteins where in which
C-terminal amino acids were individually mutated. Although actual
epitopes are still unknown for the majority of MAbs examined in this
study, information described by Yang et al. (28)
facilitates interpretation of ISU15B and ISU15C binding activities with
the C-terminal point mutants. In their studies using 70 different PRRSV
isolates, single amino acid substitutions responsible for abolishing
binding of MAbs ISU15B and ISU15C were found in the C terminus.
Substitution of what is typically a serine at positions 120 and 122 for
proline was shown to correlate with the destruction of ISU15B and
ISU15C specific epitopes, respectively. Furthermore, these amino acid
substitutions correlate to changes in the secondary structure of the C
terminus, as predicted by Chou and Fasman (4). In our
studies, MAbs ISU15B and ISU15C both displayed C terminus dependency.
We were able to mutate threonine at position 118 and proline at
position 121 on either side of serine 120, the amino acid found to be
necessary for ISU15B epitope formation, without disrupting ISU15B
binding (Table 2). Therefore, serine at position 120 may be a critical
residue for epitope formation. Interestingly, while the LV N protein
amino acid sequence is only 63% identical to that of North American
strains, ISU15B is able to detect the LV N protein and sequence
analysis indicates that the LV N protein possesses a serine at the
equivalent to position 120. For MAb ISU15C, mutation of proline at
position 121 adjacent to serine 122, the residue shown to be essential
for ISU15C epitope formation, abolishes MAb binding while mutation of
threonine at position 118 does not, suggesting that the extreme
C-terminal amino acids may participate in ISU15C-specific epitope
formation. The combination of results from these and previous
mutational studies of the PRRSV N protein suggests that the requirement
of the C terminus for conformation-dependent MAb binding correlates
with the proper formation of the predicted beta-sheet structure formed
by amino acids 111 to 117. Crystallographic studies will provide a
better understanding of the structure-function relationship of the N protein, and such studies are currently in progress.
This work was supported by the Ontario Ministry of
Agriculture, Food, and Rural Affairs (OMAFRA), Ontario Pork, and
Vetrepharm Animal Health.
| 1.
|
Albina, E.
1997.
Epidemiology of porcine reproductive and respiratory syndrome virus (PRRS): an overview.
Vet. Microbiol.
55:309-316[CrossRef][Medline].
|
| 2.
|
Allende, R.,
T. L. Lewis,
Z. Lu,
D. L. Rock,
G. F. Kutish,
A. Ali,
A. R. Doster, and F. A. Osorio.
1999.
North American and European porcine reproductive and respiratory syndrome viruses differ in non-structural protein coding regions.
J. Gen. Virol.
80:307-315[Abstract].
|
| 3.
|
Cavanagh, D.
1997.
Nidovirales: a new order comprising Coronaviridae and Arteriviridae.
Arch. Virol.
142:629-633[Medline].
|
| 4.
|
Chou, P. Y., and G. D. Fasman.
1977.
Beta-turns in proteins.
J. Mol. Biol.
115:135-175[CrossRef][Medline].
|
| 5.
|
Conzelmann, K.,
N. Visser,
P. van Woensel, and H. Thiel.
1993.
Molecular characterization of porcine reproductive and respiratory syndrome virus, a member of the arterivirus group.
Virology
193:329-229[CrossRef][Medline].
|
| 6.
|
Cuff, J. A.,
M. E. Clamp,
A. S. Siddiqui,
M. Finlay,
G. Barton, and J. Jpred.
1998.
A consensus secondary structure prediction server.
Bioinformatics
14:892-893[Abstract/Free Full Text].
|
| 7.
|
Dea, S.,
C. A. Gagnon,
H. Mardassi, and G. Milane.
1995.
Antigenic variability among North American and European strains of porcine reproductive and respiratory syndrome virus as defined by monoclonal antibodies to the matrix protein.
J. Clin. Microbiol.
34:1488-1493[Abstract].
|
| 8.
|
Dea, S.,
L. Wilson,
D. Therrien, and E. Cornaglia.
2000.
Competitive ELISA for detection of porcine reproductive and respiratory syndrome virus using recombinant E. coli-expressed nucleocapsid protein as antigen.
J. Virol. Methods
87:109-122[CrossRef][Medline].
|
| 9.
|
Denac, H.,
C. Moser,
J. D. Tratschin, and M. A. Hofmann.
1997.
An indirect ELISA for the detection of antibodies against porcine reproductive and respiratory syndrome virus using recombinant nucleocapsid protein as antigen.
J. Virol. Methods
65:169-181[CrossRef][Medline].
|
| 10.
|
Drew, T. W.,
J. J. M. Meulenberg,
J. J. Sands, and D. Paton.
1995.
Production, characterization and reactivity of monoclonal antibodies to the porcine reproductive and respiratory syndrome virus.
J. Gen. Virol.
76:1361-1369[Abstract/Free Full Text].
|
| 11.
|
Le Gall, A.,
O. Legeay,
H. Bourhy,
C. Arnauld,
E. Albina, and A. Jestin.
1998.
Molecular variation in the nucleocapsid protein gene (ORF7) of the porcine reproductive and respiratory syndrome virus (PRRSV).
Virus Res.
54:9-21[CrossRef][Medline].
|
| 12.
|
Loemba, H. D.,
S. Mounir,
H. Mardassi,
D. Archambault, and S. Dea.
1996.
Kinetics of humoral immune response to the major structural proteins of the porcine reproductive and respiratory syndrome virus.
Arch. Virol.
141:751-761[CrossRef][Medline].
|
| 13.
|
Meng, X.-J.,
P. S. Paul,
P. G. Halbur, and M. A. Lum.
1995.
Phylogenetic analysis of the putative M (ORF 6) and N (ORF 7) genes of porcine reproductive and respiratory syndrome virus (PRRSV): implication for the existence of two genotypes of PRRSV in the U.S.A. and Europe.
Arch. Virol.
140:745-755[CrossRef][Medline].
|
| 14.
|
Mengeling, W. L., and K. M. Lager.
2000.
A brief review of procedures and potential problems associated with the diagnosis of porcine reproductive and respiratory syndrome.
Vet. Res.
31:61-69[CrossRef][Medline].
|
| 15.
|
Meulenberg, J. J. M.,
M. M. Hulst,
E. J. de Meijer,
P. J. M. Moonen,
A. den Besten,
E. P. De Kluyver,
G. Wensvoort, and R. J. M. Moormann.
1993.
Lelystad virus, the causative agent of porcine epidemic abortion and respiratory syndrome (PEARS), is related to LDV and EAV.
Virology
192:62-72[CrossRef][Medline].
|
| 16.
|
Meulenberg, J. J. M.,
R. J. Bende,
J. M. A. Pol,
G. Wensvoort, and R. J. M. Moormann.
1995.
Nucleocapsid protein of Lelystad virus: expression by recombinant baculovirus, immunological properties, and suitability for detection of serum antibodies.
Clin. Diagn. Lab. Immunol.
2:652-656[Abstract].
|
| 17.
|
Meulenberg, J. J. M.,
A. P. van Nieuwstadt,
A. van Essen-Zandbergen,
J. N. A. Bos-de-Ruijter,
J. P. M. Langeveld, and R. H. Meloen.
1998.
Localization and fine mapping of antigenic sites on the nucleocapsid protein of porcine reproductive and respiratory syndrome virus with monoclonal antibodies.
Virology
252:106-114[CrossRef][Medline].
|
| 18.
|
Nelson, C. J.,
M. P. Murtaugh, and K. S. Faaberg.
1999.
Porcine reproductive and respiratory syndrome virus comparison: divergent evolution on two continents.
J. Virol.
73:270-280[Abstract/Free Full Text].
|
| 19.
|
Nelson, E. A.,
J. Christopher-Hennings,
T. Drew,
G. Wensvoort,
J. E. Collins, and D. A. Benfield.
1993.
Differentiation of US and European isolates of porcine reproductive and respiratory syndrome virus by monoclonal antibodies.
J. Clin. Microbiol.
31:3184-3189[Abstract/Free Full Text].
|
| 20.
|
Nelson, E. A.,
J. K. Nelson,
J. Christopher-Hennings,
K.-J. Yoon,
R. Magar, and D. A. Benfield.
1996.
Reactivity of North American PRRSV isolates with a monoclonal antibody panel, p. 88.
In
Proceedings of the 14th International Pig Veterinary Society Congress, Bologna, Italy.
|
| 21.
|
Rodriguez, M. J.,
J. Sarraseca,
J. Jarcia,
A. Sanz,
J. Plana-Duran, and I. Casal.
1997.
Epitope mapping of the nucleocapsid protein of European and North American isolates of porcine reproductive and respiratory syndrome virus.
J. Gen. Virol.
78:2269-2278[Abstract].
|
| 22.
|
Rossow, K. D.
1998.
Porcine reproductive and respiratory syndrome.
Vet. Pathol.
35:1-20[Abstract].
|
| 23.
|
Sagripanti, J. L.,
R. O. Zandonmeni, and R. Weimann.
1986.
The cap structure of simian hemorrhagic fever virion RNA.
Virology
151:146-150[CrossRef][Medline].
|
| 24.
|
Snijder, E. J.,
H. van Tol,
K. W. Pedersen,
M. J. Raamsman, and A. A. de Vries.
1999.
Identification of a novel structural protein of arteriviruses.
J. Virol.
73:6335-6345[Abstract/Free Full Text].
|
| 25.
|
Van Marle, G.,
J. C. Dobbe,
A. P. Gultyaev,
W. Luytjes,
W. J. Spaan, and E. J. Snijder.
1999.
Arterivirus discontinuous mRNA transcription is guided by base pairing between sense and antisense transcription-regulating sequences.
Proc. Natl. Acad. Sci. USA
96:12056-12061[Abstract/Free Full Text].
|
| 26.
|
Wootton, S. K.,
E. A. Nelson, and D. Yoo.
1998.
Antigenic structure of the nucleocapsid protein of porcine reproductive and respiratory syndrome virus.
Clin. Diagn. Lab. Immunol.
5:773-779[Abstract/Free Full Text].
|
| 27.
|
Wootton, S. K.,
D. Rogan, and D. Yoo.
2000.
Full-length sequence of a Canadian porcine reproductive and respiratory syndrome virus (PRRSV) isolate.
Arch. Virol.
145:2297-2323[CrossRef][Medline].
|
| 28.
|
Yang, L.,
Y.-J. Yoon,
Y. Li,
J.-H. Lee,
J. J. Zimmermann,
M. L. Frey,
K. M. Harmon, and K. B. Platt.
1999.
Antigenic and genetic variations of the 15 kD nucleocapsid protein of porcine reproductive and respiratory syndrome virus isolates.
Arch. Virol.
144:525-546[CrossRef][Medline].
|
| 29.
|
Yang, L.,
M. L. Frey,
Y.-J. Yoon,
J. J. Zimmermann, and K. B. Platt.
2000.
Categorization of North American porcine reproductive and respiratory syndrome viruses: epitope profiles of the N, M, GP5 and GP3 proteins and susceptibility to neutralization.
Arch. Virol.
145:1599-1619[CrossRef][Medline].
|
| 30.
|
Yoon, K.-J.,
J. J. Zimmerman,
S. L. Swenson,
M. J. McGinley,
K. A. Eernisse,
A. Brevik,
L. L. Rhinehart,
M. L. Frey,
H. T. Hill, and K. B. Platt.
1995.
Characterization of the humoral immune response to porcine reproductive and respiratory syndrome (PRRS) virus infection.
J. Vet. Diagn. Investig.
7:305-312[Abstract/Free Full Text].
|